Dr. Aditya V. Shreenivas, MD

Dr. Shreenivas practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Shreenivas' NPI, 1215282264, was assigned on July 16, 2012. Dr. Shreenivas graduated from JSS Medical College Mysore in 2010. Dr. Shreenivas holds California license C194081.

Dr. Shreenivas' primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Shreenivas' primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Shreenivas to 2 more home health agencies, 1 other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shreenivas practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Shreenivas' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Shreenivas is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Shreenivas' licenses on file in 3 states: California, New York and Wisconsin.

Dmand AI lists acute respiratory failure, acute stomach ulcer, chronic kidney disease, hypercalcemia, kidney failure, neutropenia, pleural effusion and sepsis among the conditions Dr. Shreenivas treats.

CMS data shows 185 Medicare services from Dr. Shreenivas across 4 procedure codes in 2024, all of them office visits, for 94 Medicare patients. Medicare paid $16,135 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 94 Medicare patients who saw Dr. Shreenivas in 2024. The largest group is 65 to 74, with 47 patients. 75% of them have high blood pressure, and 64% have high cholesterol. 38% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shreenivas' median patient age at 67, with 40% women.

In 2024, Dr. Shreenivas wrote 210 Medicare Part D claims for 57 patients. 73% of them were for generic drugs. CMS names the drug for 76 of them, across 4 drugs with 11 or more claims each, at $142,265 in total drug cost. In 2023, CMS named 49 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Shreenivas for performance year 2024, reported as part of a group. Dr. Shreenivas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shreenivas as offering telehealth.

Dmand AI links 42 papers to Dr. Shreenivas, published from 2013 to 2024. 2024 was the busiest year, with 11. The most frequent topics are Head and Neck Neoplasms, Adenocarcinoma and Antineoplastic Combined Chemotherapy Protocols. Dr. Shreenivas has published most often in Cancers (Basel). Dr. Shreenivas' most frequent co-authors are Musaddiq Javvad Awan, MD, Ben George, MD and Monica Erin Shukla.

Dmand AI links Dr. Shreenivas to 6 clinical trials, 4 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Hepatocellular, Oropharyngeal Neoplasms and Pharyngeal Neoplasms. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 13 general payments to Dr. Shreenivas from 8 drug and device companies from 2022 to 2025. Consulting fees make up the largest share, 77% of the total. Eli Lilly and Company paid the most, $2,485. It also lists 1 research payment totaling $686 in 2025.

Dr. Shreenivas graduated from JSS Medical College Mysore in 2010.

Dr. Shreenivas is in network with 12 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.